Not FDA-approved
Hormones & metabolism
Tesamorelin (off-label)
Evidence
Limited human data
Class
Growth hormone-releasing hormone analog
KEY TAKEAWAY
Tesamorelin is a 44-amino-acid analog of growth hormone-releasing hormone. The approved product is Egrifta. This entry covers off-label and compounded use. Only Egrifta is FDA-approved, for reducing excess abdominal fat in adults with HIV and lipodystrophy. Compounded or off-label uses are not FDA-approved.
Written by the Veylo editorial team · Updated
November 2026
What it is
Growth hormone-releasing hormone analog
Main uses
Approved for HIV-related abdominal fat; off-label uses are not proven
Key fact
Only Egrifta is FDA-approved, for reducing excess abdominal fat in adults with HIV and lipodystrophy. Compounded or off-label uses are not FDA-approved.
Route
Daily subcutaneous injection
Evidence strength
Limited human data
Tesamorelin is a 44-amino-acid analog of growth hormone-releasing hormone. The approved product is Egrifta. This entry covers off-label and compounded use.
It stimulates the pituitary gland to release growth hormone, which raises IGF-1.
Only Egrifta is FDA-approved, for reducing excess abdominal fat in adults with HIV and lipodystrophy. Compounded or off-label uses are not FDA-approved.
Approved for HIV-related abdominal fat; off-label uses are not proven.
Joint pain, fluid retention, higher blood sugar and injection-site reactions are possible. Raised IGF-1 levels need monitoring.
Tesamorelin (off-label): see PubMed and ClinicalTrials.gov for published studies and registered trials. No FDA drug label exists for the uses described.
Veylo content is educational and not medical advice. Peptides that are not FDA-approved are not approved for the uses described.